Found 1694 results for "cancer"
Mental health rarely commands the same urgency as cardiovascular disease or cancer in public health investment decisions, yet the scale of depression's…
Drug resistance remains one of the most frustrating obstacles in oncology, and for the millions of patients with advanced lung cancer, it can mean the…
Despite decades of public health messaging linking ultraviolet radiation to melanoma and non-melanoma skin cancers, a substantial portion of the American…
A biomarker hiding in plain sight on routine cancer scans may carry prognostic information that oncologists have largely overlooked. Every PET/CT performed…
For the roughly 5–10% of breast and ovarian cancers driven by BRCA1 loss, finding drugs that selectively kill deficient cells while sparing healthy ones…
Pancreatic cancer kills roughly 88% of patients within five years, largely because its dense, immunosuppressive tumor microenvironment renders most therapies…
Achieving viral cure from hepatitis C does not eliminate liver cancer risk — a finding with profound implications for the estimated 57 million people living…
When financial conflicts of interest are this pervasive across every decision-making node in oncology — from the researchers designing trials to the patient…
Few medical screening debates have persisted as long or as contentiously as PSA testing for prostate cancer. A decade ago, the evidence suggested screening…
Breast cancer incidence rises sharply after menopause, yet the biological mechanisms underlying that surge have remained frustratingly incomplete. New…
As millions of adults begin long-term GLP-1 and dual GLP-1/GIP receptor agonist therapy, the clinical conversation is shifting from efficacy to safety of…
Screening numbers have long served as the headline measure of healthy-aging programs, but counting how many older adults are tested reveals almost nothing…
For decades, the dominant clinical concern around testosterone in men has been its potential to fuel prostate cancer growth. This large-scale meta-analysis…
For patients carrying rare DNA-repair gene mutations in cancers that fall outside olaparib's approved indications, treatment options after standard therapies…
One of the most stubborn problems in thoracic oncology is that KRAS-mutant lung cancers — among the most common oncogene-driven malignancies — resist both…
Prostate cancer disparities between Black and White men remain one of oncology's most persistent and poorly explained gaps — and a new narrative review…
For decades, cisplatin-based chemotherapy before radical bladder removal has been the best available option for muscle-invasive bladder cancer — a disease…
Understanding how breast tumors evade immune surveillance remains one of oncology's central challenges, and any molecular axis that sits at that intersection…
For the millions of women carrying BRCA1 mutations who may one day rely on targeted immunotherapies, the accuracy of the molecular tools used to measure gene…
Understanding how immune cells commit to a specific identity — and stay committed — has profound implications for cancer immunotherapy, autoimmunity, and…